Senate Finance Provision Increasing ASP for Biosimilars Could Unlock Billions in Savings for Patients and Taxpayers

The Biosimilars Forum released the following statement in support of ASP + 8 provision:

The U.S. has lost billions in potential health care savings because of slow biosimilars growth. It’s clear we need policies that will guide physicians to lower-cost, safe and effective treatment options that reduce the financial burden for both patients and taxpayers. We look forward to continuing to work with the Senate Finance committee to implement policies that will support a robust biosimilars market.

The eight member companies of the Biosimilars Forum include Boehringer Ingelheim, Coherus BioSciences, Fresenius Kabi SwissBioSim, Merck and Co., Inc., Pfizer, Samsung Bioepis, Sandoz, Teva

For more information on the potential savings that can be realized with increased access to biosimilars visit